Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Medtronic Misses Mid-Year Mark With 'Disappointing' 3% Growth

Executive Summary

The medtech giant says slow sales in its cardiovascular and diabetes businesses while it awaits important product approvals were a drag on its overall revenues during the second fiscal quarter of 2017.

You may also be interested in...



OUS Approvals Analysis: Medtronic Records Another Stack Of Overseas Approvals

With 28 approvals, including 22 CE Marks, February 2017 was the biggest month for non-US medical device approvals on Medtech Insight’s Approvals Tracker since June last year, which had 31 approvals including 27 CE Marks.

New Products Drive Medtronic’s Revenue, Profit Growth In Q3

The medtech giant announced 6% revenue growth, led by the cardiac and vascular and diabetes groups, both of which are enjoying strong market demand for new products. Medtronic expects to continue growing revenues by about five percent annually to maintain double-digit earnings growth.

OUS Approvals Analysis: Slow Finish To 2016, But Still Ahead Of 2015

2016 finished with just two more non-US medical device approvals than 2015; December was by far the slowest month of the year for approvals from outside the US with just 11.

Related Content

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

MT104127

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel